

# Brooke E Wilson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/745254/publications.pdf>

Version: 2024-02-01

27  
papers

447  
citations

1039880

9  
h-index

752573

20  
g-index

27  
all docs

27  
docs citations

27  
times ranked

621  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. <i>Lancet Oncology, The</i> , 2019, 20, 769-780.	5.1	128
2	The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 343-354.	2.0	88
3	Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. <i>Lancet Oncology, The</i> , 2021, 22, 182-189.	5.1	47
4	Delayed diagnosis of anorectal malformations: are current guidelines sufficient?. <i>Journal of Paediatrics and Child Health</i> , 2010, 46, 268-272.	0.4	29
5	Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma. <i>Lancet Oncology, The</i> , 2018, 19, e351-e358.	5.1	22
6	Routine functional testing after percutaneous coronary intervention. <i>Acta Cardiologica</i> , 2007, 62, 143-150.	0.3	18
7	Appendectomy at a children's hospital: what has changed over a decade?. <i>ANZ Journal of Surgery</i> , 2012, 82, 639-643.	0.3	18
8	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
9	A critique of the fragility index. <i>Lancet Oncology, The</i> , 2019, 20, e552.	5.1	12
10	Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer. <i>Internal Medicine Journal</i> , 2019, 49, 1438-1442.	0.5	10
11	Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 257-267.	1.1	10
12	Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours. <i>Cancer Treatment Reviews</i> , 2021, 94, 102167.	3.4	8
13	Ecological effects of cefepime use during antibiotic cycling on the Gram-negative enteric flora of ICU patients. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 19.	0.9	6
14	Australia and New Zealand's responsibilities in improving oncology services in the Asia-Pacific: A call to action. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	6
15	Current Treatment and Future Trends of Immunotherapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, 667-677.	0.8	5
16	The value of first-line chemotherapy and targeted therapy in the treatment of breast cancer. <i>European Journal of Cancer Care</i> , 2021, 30, e13352.	0.7	4
17	Resource stratified guidelines for cancer: Are they all the same? Interguideline concordance for systemic treatment recommendations. <i>International Journal of Cancer</i> , 2022, 150, 91-99.	2.3	4
18	Patient and provider determinants of breast cancer screening among Ontario women aged 40-49: a population-based retrospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 631-640.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Dual Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancer: Just a Gambit or Real CheckMate?. <i>Cancer Cell</i> , 2020, 38, 438-440.	7.7	3
20	Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact. <i>JCO Global Oncology</i> , 2021, 7, 1074-1083.	0.8	3
21	A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time. <i>Scientific Reports</i> , 2022, 12, 6352.	1.6	3
22	Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. <i>Cancer Medicine</i> , 2021, 10, 5405-5414.	1.3	2
23	Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1433-1440.	2.3	2
24	Global Inequity and its Consequences in Radiation Oncology Research. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 509-510.	0.4	1
25	Accelerating drug access from advanced to early breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 538-546.	1.1	0
26	Prioritising access to cancer drugs. <i>Lancet Oncology</i> , The, 2022, 23, e1.	5.1	0
27	The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-345.	0.8	0